 José Costa, M.D.
Professor of Pathology and Medicine (Oncology); Vice Chair of Pathology; Director, Translational Diagnostics.
Department of Pathology
Yale University School of Medicine P.O. Box 208023 310 Cedar St., LH 108 New Haven, CT 06520-8023
Office: (203) 785-5803
Lab: (203) 785-4161
Fax: (203) 785-3585
email: jose.costa@yale.edu
-
Training:
- 1974-1975 Senoir Staff Fellow, Laboratory of Pathology, NCI, Bethesda, MD
1973-1974 Visiting Fellow, Laboratory of Pathology, Fogarty International Foundation, NCI, Bethesda, MD 1972-1973 Resident, Division of Surgical Pathology, Dept of Pathology, Washington Univ School of Medicine, St. Louis, MO 1971-1972 Resident, Anatomic Pathology, Dept of Pathology, Washington Univ School of Medicine, St. Louis, MO 1969-1971 Resident, Anatomic Pathology, Dept of Pathology, Univ of Colorado Medical Center, Denver, CO 1961-1967 - M.D., Magna Cum Laude, University of Barcelona Medical School, Spain 1958-1961 - B.A. (Sciences) Lycee Francais College International, Barcelona, Spain 1947-1958 - Schweizer Schule, Barcelona, Spain
-
Expertise:
- Oncology: carcinogenesis, tumor development and progression
-
Research Interests:
- We study the process of tumor formation in mammalian tissues and the natural history of the tumor cells. Current understanding indicates that most tumors are the progeny of a single cell, and that the transition from a normal tissue cell population to a malignant tumor is a multi-step process. Molecular genetic studies, combined with morphology, have defined stages for some of the common tumors of humans and experimental animals. We are currently focusing on the study of the earliest changes preceding tumor formation. Our approach consists of studying tissues known to be at high risk for the development of tumors, using both experimental animals and excised tissues from patients. We combine morphology, immunohistochemistry, and PCR-based technology to characterize the genetic changes found in distinct cell populations. By understanding the earliest disturbances preceding the emergence of tumors, we should be able to detect and interfere with the process of tumor formation.
Oncology, Advanced Diagnostics, Molecular Diagnostics Research Interests: Diagnosed Genetic Alterations in Tumors; Cancer Risk Detection by Mutational Load Distribution Analysis.
-
Professional Service:
- 2004-present - Advisory Board, "Nature Clinical Practice Oncology"
2003-2007 - Member, Publications Committee, International Academy of Pathology 2001-2004 - Member, National Cancer Institute IRG Parent Committee (Subcommittee D) 2003-2005 - Member, Committee on Cooperative Research, Yale University 2002-2004 - Member, Yale University "Conflict of Interest" Committee 2000-present - Member, Scientific Advisory Board, CNIO, Madrid, Spain 2000-2004 - Co-Editor in Chief, "Laboratory Investigation" 2000 - Panelist, Breast Cancer Consensus Conference, National Institutes of Health 1999-2003 - Member, Steering Committee, Early Detection Research Network (EDRN), NCI 1995-2007 - Deputy Director, Yale Comprehensive Cancer Center, New Haven, CT 1995-2000 - Associate Editor, "Laboratory Investigation" 1991-1993 - Chairman, Scientific Advisory Board, ISREC, Lausanne, Switzerland 1990-1993 - Chair, Lausanne Study Section for the Fond National de la Recherche Scientifique 1986-1993 - Member, Scientific Advisory Board, ISREC, Lausanne, Switzerland 1987-1993 - Member, Editorial Board, "Virchows Archiv A"
Other Links:
Surgical Pathology
Residency Training Program
Yale Comprehensive Cancer Center
Community of Science (COS) Database
Selected Publications:Tallini G, Ghossein RA, Emanuel J, Gill J, Kinder B, Dimich AB, Costa J, Robbins R, Burrow GN, Rosai J. (1998) Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. Journal of Clinical Pathology, Vol 16(3): 1158-1166.
Dillon DA, Howe CL, Bosari S, Costa J. (1998) The molecular biology of breast cancer: Accelerating clinical applications. Critical Reviews in Oncogenesis. 9(2): 125-140.
Bautista D, Obrador A, Moreno V, Cabeza E, Canet R, Benito E, Bosch X, Costa JC. (1997) Ki-ras mutation modifies the protective effect of dietary monounsaturated fat and calcium on sporadic colorectal cancer. Cancer Epidemiology, Biomarkers, and Prevention 6: 57-61.
Pinto MM, Emanuel JR, Chaturvedi V, Costa JC. (1997) Ki-ras mutations and the carcinoembryonic antigen level in fine needle aspirates of the pancreas. Acta Cytologica, 41 (2): 427-434.
Fazeli A, Steen RG, Dickinson SL, Bautista D, Dietrich WF, Bronson RT, Bresalier RS, Lander Es, Costa JC, Weinberg RA. (1997) p53, apoptosis and colon cancer, PNAS.
Guillou L, Coindre J.M, Bonichon F, Biu NB, Terrier P, Collin F, Vilain M.O, Mandard A.M, ld Doussal V, Leroux A, Jacquemier J, Duplay H, Sastre X, Costa J.C. (1997) A comparative study of the NCI and FNCLLL grading systems in a population of 410 adult patients with a soft tissue sarcoma. J Clinical Oncology 15: 350-362.
Search PubMed Database for José Costa
This page was last modified on: 09/19/2008
|